Engrail Therapeutics Extends Series A Financing to $64 Million

SAN DIEGO–(BUSINESS WIRE)–Engrail Therapeutics™ (Engrail) (the Company), a neuroscience company focused on the acquisition, development and commercialization of patient-centric therapies, today announced the close of a $32 million extension of its Series A financing round, which brings the total round to $64 million. Nan Fung Life Sciences (NFLS), the global investment platform of the Nan Fung Group, led this round following their leadership of the original Series A raise. The post Engrail Therapeutics Extends Series A Financing to $64 Million appeared first on Engrail Precision Neuroscience .